#USA #San Francisco #Atopic Dermatitis #Nektar Therapeutics #Rezpegaldesleukin

Nektar Therapeutics Initiates Global Phase 3 Trials for Atopic Dermatitis Treatment

Nektar Therapeutics, a clinical-stage biotech company based in San Francisco, has announced the initiation of two significant global registrational trials in its Phase 3 ZENITH AD program. These trials, named ZENITH AD-1 and ZENITH AD-2, will assess the effectiveness of rezpegaldesleukin in treating patients aged 12 years and older suffering from moderate-to-severe atopic dermatitis.

Rezpegaldesleukin, a first-of-its-kind regulatory T-cell biologic, aims to correct immune system imbalances that contribute to chronic inflammatory diseases, including atopic dermatitis. The initiation of these pivotal studies comes after positive results from a Phase 2b study, indicating its potential as a viable treatment option. The program will enroll 1,530 participants, reflecting Nektar's commitment to addressing the unmet needs in this patient population.

Understanding the ZENITH AD Program

The ZENITH AD program comprises three critical studies. The first two, ZENITH AD-1 and ZENITH AD-2, will include patients who have never been treated with systemic biologics or JAK inhibitors. The third study, ZENITH AD-3, caters to those who have a history of treatment with these agents. Each trial involves a rigorous design: a 24-week blinded induction period followed by a 28-week maintenance period for qualifying patients. The primary endpoint focuses on achieving an Investigator's Global Assessment (IGA) score of 0 or 1, which denotes clear or almost clear skin.

The anticipation of the initial Phase 3 results is set for mid-2028, with a filing for biologics license approval (BLA) planned for 2029. This timeline highlights the urgency and importance Nektar places on developing this novel treatment.

The Promise of Rezpegaldesleukin

Rezpegaldesleukin is designed to stimulate the growth of regulatory T-cells, which are essential for maintaining immune balance. Dr. Howard W. Robin, President of Nektar Therapeutics, emphasized that this new therapy represents a crucial step in providing patients with improved therapeutic options, especially since many existing treatments do not achieve satisfactory results for all patients.

In addition to its application in atopic dermatitis, rezpegaldesleukin is being evaluated for other autoimmune conditions, showcasing its broad therapeutic potential. Nektar's plans extend to initiating a single registrational Phase 3 trial for alopecia areata in early 2027, driven by strong data from previous studies.

A Patient-Centric Approach

Mary A. Tagliaferri, M.D., Nektar's Chief Medical Officer, underlined the clinical need for more effective and lasting treatments for atopic dermatitis, given that many patients do not experience durable control of their disease with current therapies. The company's innovative approach aims to restore T-reg function upstream of inflammatory pathways, potentially offering a significant change in treatment paradigms.

The ZENITH AD trials also consider comorbid conditions. The design includes assessments for asthma control in patients with a history of asthma, addressing the complex interplay between atopic dermatitis and other health issues.

Conclusion

As Nektar Therapeutics embarks on this vital Phase 3 journey, the biotech industry's eyes will be on the outcomes of these trials. The commitment to innovation and improving patient care in autoimmune diseases reflects the evolving landscape of treatment possibilities for conditions once deemed challenging to manage. With rezpegaldesleukin, there is hope for transforming how moderate-to-severe atopic dermatitis is treated, promising a brighter future for millions affected by this condition.

For continual updates on the progress of the ZENITH AD program and the broader implications of rezpegaldesleukin, please stay tuned to Nektar Therapeutics and healthcare news outlets.